ALAoxue Li

Aoxue Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Aoxue Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Chunliang Liu

    Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China

    1 shared publication
  • Jun Wan

    Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China

    1 shared publication
  • Kesheng Dai

    Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China

    1 shared publication
  • Mingyan Jin

    Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China

    1 shared publication
  • Song Lyu

    Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China

    1 shared publication

Latest Publications

  • Open Access

    Potential Role of Contact Pathway Factors in Catheter-Related Thrombosis: Emerging Evidence and Therapeutic Strategies

    by Mingyan Jin, Chunliang Liu, Song Lyu, Aoxue Li, Kesheng Dai, Jun Wan

    The catheter is among the most commonly used blood-contacting medical devices, but its use can induce surface-mediated coagulation activation, leading to catheter-related thrombosis (CRT). The occurrence of CRT causes venous thromboembolism and catheter malfunction, but current antithrombotic strategies have unsatisfactory efficacy and safety profiles. Here, we review recent advances in the understanding of the pathology of CRT, particularly the roles of the contact pathway factors, and promising novel therapeutic options. Recent studies using genetically modified animals, factor-deficient plasmas, specific inhibitors and purified systems demonstrated an important contribution of contact pathway factors XII and XI to catheter-related blood clotting. Accordingly, contact pathway inhibition has efficacy comparable to that of heparins in mitigating catheter-related coagulation or intraluminal occlusion in various in vitro and animal models, while having lower bleeding risk. Early human studies suggest potential thromboprotective effects of FXI inhibition in catheter placement and hemodialysis settings. However, inhibition of factors XII or XI may impair the defense against infection or disturb normal cardiac function, respectively. Larger human trials are needed to further confirm the efficacy and safety of these contact pathway inhibitors, and to explore whether low-dose combinations of contact pathway inhibitors with heparins are more effective for CRT protection.